Anivance AI stands at the forefront of intelligent healthcare innovation, specializing in human organ model solutions. A decade of experience with respiratory models has driven us to achieve significant advancements in preclinical testing and earned us the prestigious 2023 Moderna Taiwan mRNA Innovation Award. This recognition is a testament to our unwavering commitment to improving healthcare and reflects our mission: Saving Lives: Now a Reality. Our comprehensive services, designed to accelerate the drug discovery and safety assessment processes, leverage human-simulated data to bridge the gap between laboratory findings and clinical applications. By precisely simulating human responses, we provide the pharmaceutical industry with powerful tools for thorough safety and efficacy evaluation. | Anivance AI is bridging Taiwan’s world-class semiconductor and manufacturing expertise with AI and life sciences, creating a new era of intelligent drug discovery. By integrating AI-powered organ-on-chip technology with automated high-throughput research, we provide pharmaceutical companies with a scalable, self-optimizing platform that accelerates preclinical testing and delivers breakthrough insights. Unlike traditional preclinical models, our platform is continuously learning and adapting, optimizing experiment design, mechanistic analysis (MOA), and real-time data interpretation. By embedding AI agents into automated research workflows, we help pharmaceutical companies make faster, smarter, and more data-driven decisions, significantly reducing preclinical failure rates and improving R&D efficiency. With 25 granted and pending patents, Anivance AI collaborates with leading global pharmaceutical companies and six clinical institutions, ensuring that our technology is aligned with real-world drug development needs. We have validated our high-throughput organ-on-chip platform in lung, liver, and oncology models, with expanding applications in autoimmune diseases and cardiovascular research. Our breakthroughs in inhalable nanoparticle delivery and respiratory disease modeling have earned global recognition, including a nomination for the LUSH Prize in Science. By leveraging Taiwan’s semiconductor supply chain and precision manufacturing ecosystem, we deliver a new level of automation, AI-driven analytics, and experimental scalability that was previously unattainable in biotech. Backed by two of Taiwan’s largest publicly traded companies and validated by over 50 collaborating physicians, Anivance AI is one of Taiwan’s fastest-growing biotech startups, now expanding into the global market. We are not just developing technology—we are reshaping the future of AI-powered drug discovery. With a foundation built on semiconductor precision, AI intelligence, and biotech innovation, Anivance AI provides pharmaceutical companies with the tools to make transformative breakthroughs, faster than ever before. | Anivance AI is a deep tech company developing Physical AI infrastructure for decision-grade human biology in early drug development and translational research. Rather than operating as a service provider or a single model technology, Anivance AI is designed as an integrated system. Physical organ models function as the sensing layer. Standardized execution and biological baselines form the control layer. Structured data intelligence provides the reasoning layer. Together, these components support closed loop experimentation and decision making. We integrate three tightly coupled layers into a single Physical AI platform. 1. Engineering grade physical organ systems Hard structured organ on chip and microphysiological systems designed for long term stability and reproducible operation under dynamic physiological conditions. The systems support continuous microfluidic circulation, vascular side dosing, dynamic exposure workflows including inhalation relevant conditions, and long duration experiments. 2. Standardized biological baselines and profiles Reusable organ and disease profiles that define execution and interpretation standards, reduce variability across batches and operators, and enable cross study comparability. 3. Human data foundry and decision loop Integrated imaging, functional readouts, and structured experimental metadata form a continuously accumulating human data infrastructure. This supports AI assisted analysis, iterative model refinement, and decision oriented reporting aligned with regulatory expectations. The platform has been deployed across lung and inhalation, liver, kidney, CNS and BBB, oncology, and rare disease applications, supporting more than 25 experimental programs across North America, Japan, South Korea, and Europe. | Anivance AI Corporation is a tech startup integrating miniaturized human organ systems on chips with Multi-Agent AI to accelerate drug discovery. Backed by 35 patents and thousands of data points across multiple organ and disease models, Anivance AI advances 20+ projects and expands across North America, Japan, South Korea, and Europe.
Andelyn Biosciences
Our Vision: Pioneering Solutions that turn Hope into Reality Our Mission: Accelerating the development and manufacturing of innovative therapies to bring more treatments to more patients Andelyn Biosciences (https://www.andelynbio.com/) is pioneering solutions that turn hope into reality as a cell and gene therapy CDMO. Capabilities span viral vector process and analytical development, small to large scale adherent and suspension based GMP manufacturing up to 2000L. Having 20+ years of experience with viral vector manufacturing, Andelyn offers access to globally recognized thought leaders with troubleshooting/characterization expertise and GMP material produced for 75+ worldwide clinical trials. In addition to producing 400+ cGMP clinical batches, Andelyn provides research and tox grade plasmids with an additional offering of GMP plasmid manufacturing, full quality system/regulatory support and supply chain vertical integration. Its state-of-the-art 185,000 sq ft commercial manufacturing facility will expand capacity across 8+ production suites for customization of new programs and tech transferred programs, offering clinical through commercial-scale capabilities that will help accelerate innovative therapies to bring more treatments to more patients. Gene and cell therapy, AAV viral vector manufacturing, Plasmid Manufacturing, Lentiviral vector Manufacturing, Commercial Manufacturing, CDMO, analytical method development, GMP, fill finish, QC/QA release testing, Process Characterization, Regulatory Affairs, Licensing Andelyn Biosciences is a pioneering cell and gene therapy organization born out of Nationwide Children’s Hospital, where the first FDA-approved systemic gene therapy was discovered. See all our Press Releases at: https://www.andelynbio.com/media-center | Andelyn Biosciences (https://www.andelynbio.com/) is pioneering solutions for Turning Hope into Reality (TM) as a gene therapy CDMO. Capabilities span viral vector process and analytical development, small to large scale adherent and suspension based GMP manufacturing up to 2000L. With 20+ years of experience in viral vector manufacturing, Andelyn offers access to globally recognized thought leaders with troubleshooting and characterization expertise and GMP material produced for 75+ worldwide clinical trials. In addition to producing 450+ cGMP sublots, Andelyn provides research, tox, and GMP grade plasmids Andelyn also has full quality and regulatory support and supply chain vertical integration. Its state-of-the-art 185,000 sq ft commercial manufacturing facility offers capacity across 16 production suites for customization of new programs as well as tech transfer programs, offering clinical through commercial-scale capabilities that will help accelerate innovative therapies to bring more treatments to more patients. Andelyn Biosciences is a pioneering gene therapy CDMO born out of Nationwide Children’s Hospital, where the first FDA-approved systemic gene therapy was discovered. | Andelyn Biosciences is a full-service cell and gene therapy CDMO focused on the development, characterization and production of viral vectors for gene therapy. With more than 20 years of experience, Andelyn’s deep scientific expertise has resulted in the production of cGMP material for more than 450 clinical batches and 75 global clinical trials. Operating out of its development and manufacturing facilities in Columbus, Ohio, Andelyn supports its clients in developing cell and gene therapies from concept through plasmid engineering and manufacturing, process and analytical development, and cGMP clinical and commercial manufacturing. Andelyn can accelerate programs and deliver high quality products by developing and manufacturing processes on its configurable, data-driven AAV CuratorTM Platform, or tech transferring in an established client program. Capabilities include cGMP manufacturing for suspension processes up to a 2,000-liter and adherent processes. A rigorous quality system, regulatory support, and supply chain vertical integration further support clients in bringing their critical therapies to market. For more information, visit andelynbio.com. For Andelyn media inquiries, please contact: media@andelynbiosciences.com
AnchorBio Solutions
AnchorBio Solutions provides a diverse set of high value biology-focused preclinical drug discovery services to accelerate pharma/biotech R&D and diagnostics discovery and development. We provide services in target discovery and validation, screening and profiling, biomarker discovery and development, and sample analysis and testing with scalable capabilities and workflows. | AnchorBio Solutions provides a diverse set of high value biology-focused preclinical drug discovery services to accelerate pharma/biotech R&D and diagnostics discovery and development. AnchorBio specializes in basic biological research and bioanalytical services with scalable capabilities and workflows in the following areas: -Target Identification, Validation and Screening AnchorBio has the expertise and experience required to take you from initial target identification and validation to hit identification and lead optimization. -Biomarker Discovery and Development Untargeted and targeted cell, tissue and plasma proteomics capabilities. -In Vitro Assay Services AnchorBio has the expertise to perform a wide range of assays designed to support your research needs, as well as the experience and creativity to develop assays to meet your specific unique requirements. -Antibody Services AnchorBio offers full-service custom monoclonal and polyclonal antibody development, from immunogen design through scale-up, purification, and characterization. Our complete portfolio of antibody services also includes custom antibody labelling, conjugations, and assay development. -Protein Services AnchorBio specializes in custom protein design, expression, and purification to offer fully customized solutions to meet the diverse needs of researchers. -Cell Biology Custom cell biology services from cell line engineering and characterization to functional assays and high-throughput screening. With decades of experience, our team is committed to your success.
AmbioPharm, Inc.
AmbioPharm is a global leader in peptide manufacturing, specializing in the development and production of peptide-based Active Pharmaceutical Ingredients (APIs). Founded in 2005 and headquartered in North Augusta, South Carolina, USA, we are a patient-focused Contract Development and Manufacturing Organization (CDMO) with a reputation for technical excellence, innovation, and cost-effective solutions. Our state-of-the-art facilities in South Carolina, USA, and Shanghai, China, manufacture New Chemical Entities (NCEs) and peptide APIs under cGMP compliance, supporting pharmaceutical and biotech clients worldwide. AmbioPharm provides comprehensive peptide manufacturing solutions that support our clients from early-stage development through full-scale commercial production. Our expertise covers solid-phase, solution-phase, and hybrid synthesis, as well as organic conjugations to proteins, toxoids, antifungals, KLH (Keyhole Limpet Hemocyanin), and PEG (Polyethylene Glycol). We offer end-to-end peptide development services, including scale-up, validation, and process qualification leading up to New Drug Application (NDA) submissions with the U.S. Food and Drug Administration (FDA). With our advanced manufacturing facilities, robust quality systems, and cost-effective approach, AmbioPharm is the trusted partner for pharmaceutical and biotech companies seeking high-quality peptide APIs for both clinical and commercial applications. | AmbioPharm is a global peptide CDMO founded in 2005 and headquartered in North Augusta, South Carolina, USA specializing in developing highly efficient manufacturing processes for peptide-based Active Pharmaceutical Ingredients (APIs) at clinical and commercial stages. In our manufacturing facilities in South Carolina, USA and Shanghai, China, we manufacture New Chemical Entities (NCEs) under cGMP for clients worldwide. Both facilities have been inspected multiple times by the FDA as well as other global regulatory bodies with excellent outcomes. Our mission is to accelerate your peptides to patients.
Altruist Biologics
Altruist Biologics is a fully integrated CDMO, focusing on the development and commercial manufacturing of antibodies, fusion proteins, ADCs, cell and gene therapies, and other drugs. From cell line development to aseptic fill/finish, we are committed to supporting our clients develop affordable and high-quality biopharmaceuticals for the benefit of patients worldwide. We offer a total 60KL capacity at our Suzhou site, and commenced partial operations at our new Hangzhou facility with the completion of four 20KL bioreactors, one of the largest of its kind. The site will hold a total capacity of 172KL when it becomes fully completed in the second half of 2024. Guided by the values of “Perseverance for Altruism, Ingenuity for Sustainability,” we continuously strengthen our capabilities and quality systems in line with anticipated market and client needs to provide the most efficient and cost-effective services. | Altruist Biologics is a fully integrated CDMO, focusing on the development and commercial manufacturing of antibodies, fusion proteins, ADCs, and other drugs. From cell line development to aseptic fill/finish, we support our clients in producing affordable, high-quality biopharmaceuticals for the benefit of patients worldwide. We offer a total 60KL capacity at our Suzhou site, meeting the GMP requirements of the FDA, EMA, and NMPA, and commenced partial operations at our new Hangzhou facility with the completion of four 20KL bioreactors, the first and largest of its kind in China. The site will hold a total capacity of 172KL when it becomes fully completed in 2025. Altruist offers an end-to-end solution that includes: > Cell line development, process development/optimization, formulation development, analytical method development > Clinical sample production (200L/500L/1,000L/3,000L, liquid/lyo/PFS/AI), PCPV, BLA filing, PAI > Commercial manufacturing (3,000L/4,500L/20,000L, liquid/lyo/PFS/AI) > One-stop, integrated ADC platform: CMC development, clinical and commercial manufacturing for drug substance and drug product Building on our accumulated expertise and advanced technologies, we continuously strengthen our capabilities and quality systems in line with anticipated market needs, providing accessible services while accelerating your path to patients.
AlpalifeBio
AlpalifeBio is a contract research organization focused on VHH discovery and functional verification services. We have established VHH discovery platform, antibody engineering platform, quality analysis platform and protein purification platform with multiple expression systems, including bacteria, yeast, insect and mammalian cell expression systems, providing one-stop solution for VHH custom discovery. | AlpalifeBio provides customized services for nanobody drugs R&D at various stages, such as nanobody/VHH discovery, humanization, affinity maturation and cell-based functional evaluation. We also provide services of expression, purification, and functional evaluation of GPCRs, an important family of drug target proteins. | AlpalifeBio is a contract research organization focused on VHH discovery and functional verification services. We have established VHH discovery platform, antibody engineering platform, quality analysis platform and protein purification platform with multiple expression systems, including bacteria, yeast, insect and mammalian cell expression systems, providing one-stop solution for VHH custom research. Also, we have anti-tag VHH products (such as VHHs against FLAG, HA, MYC, GFP, mCherry, mIgG) and proteases (such as 3C, TEV, SUMO). | AlpalifeBio thrilled to announce that Professor George F. Gao, a globally recognized scientist and leader in immunology, virology, and biotechnology, has joined AlpalifeBio as our Technical Support Chief Scientist. His extensive experience and groundbreaking research will further strengthen our commitment to advancing single-domain antibody (VHH) research and therapeutic applications.
Alcyomics
Alcyomics a proven, experienced CRO and service-provider, Alcyomics has developed unique non-animal non-artificial human based in vitro assays that transform drug development by enabling early and accurate identification of safe and efficacious compounds. Our sensitive and highly customisable assays significantly improve the testing process making it faster, more effective and better at predicting clinical outcomes. We help clients reduce the cost of drug development, reduce the use of animal models and improve speed to market whilst providing a better return on investment. Our platform is fully human, sensitive and a cost effective approach for both toxicity and efficacy studies.
Agilex Biolabs
Agilex Biolabs, Australia’s largest and most technologically advanced regulated bioanalytical and GLP toxicology laboratory, has been delivering bioanalytical services for non-clinical studies and clinical trials for over 28 years. Agilex boasts world-class facilities equipped with cutting-edge equipment, including 17 Sciex API LC-MS/MS mass spectrometers to measure small molecule drugs, including novel chemical entities, nucleotides, enantiomers, peptides. Their immunoassay and immunobiology laboratories feature state-of-the-art equipment for large molecule bioanalysis, such as Gyrolab xPlore, MSD Quickplex 120, BD FACSymphony A3 flow cytometers, and BioRad droplet digital quantitative real-time analysers for RNA, siRNA, and miRNA clinical trials, including vaccines and gene therapy trials. Agilex also offers a range of rodent toxicology, including non-GLP and GLP toxicology services and pharmacokinetics studies, to support preclinical through to early/late-phase clinical programs at its custom-built, state-of-the-art GLP facility in Brisbane, Australia. With expertise in all types of molecules, laboratory species, routes of administration, and non-clinical studies, in addition to multiple certifications such as ISO/IEC17025 accreditation and OECD GLP recognition with NATA, Agilex ensures the highest quality standards for seamless end-to-end testing from preclinical to clinical analysis. As a proud member of the Healius network and through its partnership with global laboratory provider SGS, Agilex Biolabs offers a one-stop-shop package to support multi-region drug development from preclinical to late phase, accelerating hundreds of nonclinical and clinical trials for sponsors from the USA, APAC, and Europe.
ActivInsights
ActivInsights is a Digital Health company. ActivInsights delivers activity, sleep and lifestyle insight to healthcare professionals. We simplify access to real-world patient data with our wearables, connected technologies and secure data infrastructure. With a commitment to improving global public health, ActivInsights is accelerating pharmaceutical drug development, enhancing clinical practice and improving disease management. Our high resolution wearable technologies are designed to be very low burden for long-term continuous wear for participants. We offer a true, unfiltered tri-axial raw data acceleroemeter, the GENEActiv, and a near-real time device, the Activinsights Band for long-term wear. The wearables achieve high compliance and adherence, are cost-effective and enable objective insights into physical activity, gait and mobility, sleep, lifestyle and disease progression. Babies as young as 8 weeks old have worn the devices, up to older adults on the wrist. ActivInsights technologies can be deployed in an array of therapeutic areas to truly understand the patient’s wellbeing in a free living environment, outside of the clinic. We offer seamless integration into existing platforms and can support data processing and analysis services to deliver meaningful digital biomarkers and objective outcome assessments.
Accelsiors Gmbh
Accelsiors is a global, full-service CRO accelerating clinical development with AI-driven insights, Quality by Design (QbD), and patient-centric solutions. From Phase I to regulatory approvals, we optimize trial execution, ensuring speed, compliance, and success. Visit us at BIO 2025 in the German Pavilion to explore how we can advance your next clinical breakthrough. At Accelsiors CRO, we accelerate biopharmaceutical innovation through a science-driven, patient-centric approach. As a global, full-service CRO, we provide tailored clinical trial solutions designed to de-risk development, optimize timelines, and bring transformative therapies to market faster. With a proven track record in global clinical development, we navigate the complexities of modern drug research—from early-stage clinical development to regulatory approvals and patient-centric trials. Our strategic approach, cutting-edge AI analytics, and deep therapeutic expertise ensure seamless execution and measurable outcomes. | Accelsiors CRO – Science-Driven Clinical Excellence Accelsiors is a global, full-service CRO accelerating clinical development with AI-driven insights, Quality by Design (QbD), and patient-centric solutions. From Phase I to regulatory approvals, we optimize trial execution, ensuring speed, compliance, and success. Visit us at BIO 2026 in the German Pavilion to explore how we can advance your next clinical breakthrough. Let’s discuss how we can accelerate your next clinical breakthrough with Accelerant™, our proprietary Penta-Helix approach—a unique integration of science, patient-centricity, Quality by Design, AI-driven state-of-the-art technologies, and speed with cost-effectiveness at every stage of clinical development.